eBioscience Takes Over Bender MedSystems

eBioscience has acquired Bender MedSystems in an all cash transaction. The acquisition will provide eBioscience with over 1,000 high profile immunology and oncology products including the Instant ELISA and FlowCytomix brands that target the life sciences and diagnostics markets.

Bender MedSystems’ novel bead based multiplexing technology and products, marketed and sold under the FlowCytomix brand, allow researchers to analyse simultaneously up to 20 proteins in a single reaction.

The company said that the scalable technology platform can be combined with many of eBioscience’s existing technologies that the company plans to use in the development of a significant number of expanded sets of cell analysis product lines.

Todd Nelson, CEO of eBioscience, said: Bender MedSystems provides us with a cutting-edge technology platform that, when combined with many of eBioscience’s leading cell analysis research and diagnostic products, will facilitate the accelerated development and commercialisation of breakthrough innovations.

“The Bender MedSystems’ acquisition builds on eBioscience’s recent expansion in Europe and is complementary to the company’s NatuTec operations in Germany. In addition to providing eBioscience with a first class center of excellence for the development of immunoassays in Europe, the company will now have manufacturing, enhanced customer service, technical support and increased regional distribution capabilities. Bender MedSystems will serve as eBioscience’s European headquarters and will greatly enhance the ability to get products to customers more rapidly and reliably.

The FlowCytomix reagents are designed to run on existing flow cytometry instruments, allowing eBioscience to take full advantage of our current commercial channel without having to invest into an instrument platform. Accordingly, the technology represents an exceptional opportunity for us to increase our presence within the multiplexing segment of the immunoassay market.